What is the immunoglobulin (Ig) most frequently increased in multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IgG is the Immunoglobulin Most Frequently Increased in Multiple Myeloma

The correct answer is D. IgG is the most frequently increased immunoglobulin in multiple myeloma, accounting for approximately 50-60% of all cases. 1

Distribution of Immunoglobulin Types in Multiple Myeloma

Multiple myeloma is characterized by the proliferation of malignant plasma cells that typically produce a monoclonal immunoglobulin (M-protein). The distribution of immunoglobulin types in multiple myeloma follows a consistent pattern:

  • IgG: 50-60% of cases - Most common immunoglobulin type 1, 2
  • IgA: 20-25% of cases - Second most common 2
  • Light chain only (Bence-Jones): 15-20% of cases - Produces only light chains without heavy chains
  • IgD: 2% of cases - Rare
  • IgM: 0.5% of cases - Very rare in multiple myeloma (more commonly associated with Waldenström's macroglobulinemia)
  • Biclonal gammopathy: 5% of cases - Two different M-proteins present simultaneously 2
  • Non-secretory: 3% of cases - No detectable M-protein in serum or urine 1

Diagnostic Significance

The identification of the specific immunoglobulin type is crucial for:

  1. Diagnosis confirmation: The NCCN guidelines specify that detection and characterization of the M-protein by immunofixation is essential for diagnosing multiple myeloma 1

  2. Disease monitoring: The same test must be used for serial studies to ensure accurate relative quantification of the M-protein 1

  3. Risk stratification: Non-IgG myeloma is considered a risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) 3

Clinical Implications of Immunoglobulin Type

Different immunoglobulin types may be associated with specific clinical features:

  • IgG myeloma: Generally has a more indolent course compared to other types
  • IgA myeloma: More frequently associated with extramedullary disease
  • Light chain myeloma: Higher risk of renal complications and amyloidosis
  • IgD myeloma: Often presents with more aggressive disease and poorer prognosis
  • IgM myeloma: Extremely rare; must be distinguished from Waldenström's macroglobulinemia

Diagnostic Workup

When evaluating for multiple myeloma, the following tests should be performed to identify and characterize the M-protein:

  • Serum protein electrophoresis (SPEP)
  • Serum immunofixation electrophoresis (SIFE)
  • Quantitative immunoglobulin levels (IgG, IgA, IgM)
  • Serum free light chain assay
  • 24-hour urine protein electrophoresis (UPEP)
  • Urine immunofixation electrophoresis (UIFE)

Conclusion

While multiple myeloma can be associated with various immunoglobulin types, IgG is by far the most common, representing more than half of all cases. This is followed by IgA, while IgM and IgD are rare in multiple myeloma.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Immunoglobulin heavy and light chain isotypes in multiple myeloma patients.

Asian Pacific journal of cancer prevention : APJCP, 2007

Guideline

Management of Monoclonal Gammopathy of Undetermined Significance (MGUS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.